ES2635019T3 - Vacuna con vector del herpesvirus de pavo contra la gripe aviar en aves de corral - Google Patents

Vacuna con vector del herpesvirus de pavo contra la gripe aviar en aves de corral Download PDF

Info

Publication number
ES2635019T3
ES2635019T3 ES11771123.4T ES11771123T ES2635019T3 ES 2635019 T3 ES2635019 T3 ES 2635019T3 ES 11771123 T ES11771123 T ES 11771123T ES 2635019 T3 ES2635019 T3 ES 2635019T3
Authority
ES
Spain
Prior art keywords
vaccine
avian influenza
poultry
herpesvirus vector
twenty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11771123.4T
Other languages
English (en)
Inventor
Paulus Jacobus Antonius Sondermeijer
Iwan Verstegen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Application granted granted Critical
Publication of ES2635019T3 publication Critical patent/ES2635019T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Vector de herpesvirus de pavo (HVT) que comprende un ácido nucleico heterólogo que comprende una secuencia de nucleótidos que codifica una proteína hemaglutinina (HA) de virus de la gripe aviar (VGA), caracterizado por que dicha secuencia de nucleótidos está unida operativamente a un promotor génico de glucoproteína 5 B (gB) de un herpesvirus de mamífero.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
*) Cuando se ensaya en un ensayo de IH con otro antígeno de tipo H5, hubo una prueba clara de seroconversión, con títulos de IH de 6,7 y 8,6, a las 2 y 3 semanas p.v. respectivamente.
Tabla 2: protección contra señales clínicas de GA, en SPE, vacunados i.m. a un día de edad, después de exposición letal (<48 h) con H5N1 de VGA AP.
Vacuna
n.º de animales Protección contra señales clínicas
Exp. a las 2 semanas p.v.
Exp. a las 3 semanas p.v.
HVP142
20 0/10 1/10
HVP310
19 10/10 9/9
HVP311
20 10/10 10/10
H5 inac
20 3/10 8/10
diluyente
10 0/5 0/5
Tabla 3: protección contra reaislamiento de virus, en SPE, vacunados i.m. a un día de edad, después de exposición letal (<48 h) con VGA HSN1 AP.
Vacuna
n.º de animales Positivo en reaislamiento de virus (tráquea)
Exp. a las 2 semanas p.v.
Exp. a las 3 semanas p.v.
HVP142
20 10/10 10/10
HVP310
20 6/10 1/10
HVP311
20 6/10 2/10
H5 inac
20 10/10 10/10
diluyente *)
0 - -
*) No se pudieron tomar hisopos de animales en el grupo de diluyente ya que todos murieron en un periodo de 48 horas después de la exposición
3. Ensayo animal en pollos MDA+
10 3.1. Preparación de ensayo animal
La disposición del ensayo animal en polluelos de engorde MDA+ fue en general la misma que para el ensayo de pollos SPE excepto que no se incluyó vacuna de vector HVP142. Los polluelos de engorde MDA+ derivaron de progenitores que se habían vacunado dos veces con una vacuna de emulsión H5N2 inactivada convencional; los
15 polluelos tuvieron títulos de IH de H5 de partida entre 5 y 6.
3.2. Resultados
Los resultados de los ensayos en pollos MDA+ se presentan en las Tablas 4-6.
20 Para las Tablas 5 y 6 se aplican las mismas observaciones que para las Tablas 2 y 3 anteriores.
Tabla 4: títulos de IH el día de la exposición, en MDA+ vacunados i.m. a un día de edad
Vacuna
n.º de animales IH (log2, ag. H5N1 AP)
Exp. a las 2 semanas p.v.
Exp. a las 3 semanas p.v.
HVP310
20 <4 5,4
HVP311
20 <4 4,4
H5 inac
20 <4 <4
diluyente
10 <4 <4
15
imagen14
imagen15

Claims (1)

  1. imagen1
ES11771123.4T 2010-10-18 2011-10-17 Vacuna con vector del herpesvirus de pavo contra la gripe aviar en aves de corral Active ES2635019T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US407724P 2002-09-03
EP10187948 2010-10-18
EP10187948 2010-10-18
US40772410P 2010-10-28 2010-10-28
PCT/EP2011/068073 WO2012052384A1 (en) 2010-10-18 2011-10-17 Herpesvirus of turkeys vectored vaccine against avian influenza in poultry

Publications (1)

Publication Number Publication Date
ES2635019T3 true ES2635019T3 (es) 2017-10-02

Family

ID=43587599

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11771123.4T Active ES2635019T3 (es) 2010-10-18 2011-10-17 Vacuna con vector del herpesvirus de pavo contra la gripe aviar en aves de corral

Country Status (8)

Country Link
US (1) US8986987B2 (es)
EP (1) EP2629794B1 (es)
CN (1) CN103370079B (es)
ES (1) ES2635019T3 (es)
HU (1) HUE033739T2 (es)
MX (1) MX344069B (es)
PL (1) PL2629794T3 (es)
WO (1) WO2012052384A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103667351B (zh) * 2012-09-10 2017-01-25 中国农业科学院哈尔滨兽医研究所 以鸭病毒性肠炎病毒疫苗株为载体的重组病毒疫苗在鸡形目禽类中的应用
WO2015023461A2 (en) * 2013-08-06 2015-02-19 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CN106031793B (zh) * 2015-03-13 2020-12-01 普莱柯生物工程股份有限公司 一种活疫苗及其制备方法和应用
WO2017027324A1 (en) 2015-08-10 2017-02-16 The Texas A&M University System Recombinant turkey herpesvirus vaccines and uses thereof
ES2935643T3 (es) 2016-06-17 2023-03-08 Intervet Int Bv Construcciones de virus de la enfermedad de Marek no patógeno recombinante que codifican antígenos del virus de la laringotraqueítis infecciosa y del virus de la bursitis infecciosa
JOP20190088A1 (ar) * 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
CN106497893A (zh) * 2016-10-28 2017-03-15 扬州大学 表达H7N9亚型禽流感病毒嵌合型血凝素蛋白的重组火鸡疱疹病毒株rHMW及构建方法
CN106399267A (zh) * 2016-10-28 2017-02-15 扬州大学 表达H7N9亚型禽流感病毒血凝素蛋白的重组火鸡疱疹病毒株rHOH及构建方法
CN107296956A (zh) * 2017-06-29 2017-10-27 青岛易邦生物工程有限公司 一种基因重组活载体疫苗
CN109666656A (zh) * 2019-01-23 2019-04-23 北京市农林科学院 一种纯化重组鸡传染性法氏囊病毒vp2基因的马立克氏病病毒cvi988株的方法
CN110205308A (zh) * 2019-05-24 2019-09-06 华南农业大学 一种表达ha基因的重组火鸡疱疹病毒及其应用
US12589147B2 (en) * 2019-12-20 2026-03-31 Intervet Inc. Multivalent HVT vector vaccine
BR112023004123A2 (pt) 2020-09-07 2023-04-04 Intervet Int Bv Vacina de haste da ha para alvos positivos de anticorpos de ha
EP4267179A1 (en) 2020-12-24 2023-11-01 Intervet International B.V. Multivalent hvt vector vaccine
MX2024000544A (es) 2021-07-13 2024-04-09 Intervet Int Bv Superacion de la interferencia de los anticuerpos en las aves.
JP2025515050A (ja) 2022-05-05 2025-05-13 インターベット インターナショナル ベー． フェー． 新規多価ｈｖｔベクターワクチン

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961982A (en) * 1985-09-06 1999-10-05 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US5928648A (en) * 1985-09-06 1999-07-27 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
ATE342996T1 (de) 1986-01-27 2006-11-15 Schering Plough Ltd Attenuierte herpesviren, herpesviren die eine aminosäuresequenz kodierende fremde dna enthalten,und diese enthaltende impfstoffe
US5731188A (en) * 1986-11-20 1998-03-24 Syntro Corporation Recombinant equine herpesviruses
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
US5919461A (en) * 1989-10-18 1999-07-06 Akzo Nobel N.V. Nonpathogenic infectious bursal disease virus and vaccine
EP0431668B1 (en) * 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
ZA923041B (en) * 1991-05-14 1993-04-28 Akzo Nv Recombinant vaccine against marek's disease
US5690939A (en) * 1991-05-14 1997-11-25 Akzo Nobel N.V. Recombinant vaccine against marek's disease
US5853733A (en) * 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US6183753B1 (en) * 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
US6913751B2 (en) * 1992-06-12 2005-07-05 Schering-Plough Veterinary Corporation Recombinant avian herpesvirus useful in vaccine production
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
US6875856B2 (en) * 1993-09-24 2005-04-05 Syntro Corporation Recombinant infectious laryngotracheitis virus and uses thereof
DK0775746T3 (da) 1995-07-03 2006-04-03 Akzo Nobel Nv Vaccine mod fjerkræcoccidiose
WO1997003187A2 (en) * 1995-07-07 1997-01-30 Nippon Zeon Co., Ltd. Marek's disease virus genes and their use in vaccines for protection against marek's disease
DE69731016T2 (de) 1996-03-04 2005-10-06 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Herstellung einer Trehalulose enthaltende Polysaccharidzusammensetzung.
ATE316139T1 (de) * 1998-07-31 2006-02-15 Akzo Nobel Nv Attenuierte pferdeherpesvirus
HUP0104881A3 (en) 1998-12-21 2003-12-29 Akzo Nobel Nv Method to produce inactivated w/o emulsion adjuvated vaccines
US6299882B1 (en) * 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
AU6698900A (en) 1999-07-16 2001-02-05 Agricultural Research Service Live recombinant vaccine against avian leukosis virus using a marek's disease virus (mdv) virus as vector
US7314715B2 (en) * 2001-06-14 2008-01-01 Schering-Plough Animal Health Corporation Recombinant avian herpesvirus useful in vaccine production
US20070178115A1 (en) * 2005-08-15 2007-08-02 Tang De-Chu C Immunization of avians by administration of non-replicating vectored vaccines
US20080241188A1 (en) * 2007-03-30 2008-10-02 Zeon Corporation Turkey herpesvirus vectored recombinant containing avian influenza genes
EP2291397A1 (en) 2008-06-23 2011-03-09 Intervet International BV Recombinant herpesvirus of turkeys encoding for interleukin-12
EP3542815A1 (en) * 2008-11-28 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Recombinant avian influenza vaccine and uses thereof
CN105567648B (zh) 2009-04-15 2019-09-03 法国诗华大药厂 用于免疫接种水禽物种的重组禽疱疹病毒载体和疫苗

Also Published As

Publication number Publication date
HUE033739T2 (en) 2018-01-29
MX2013004303A (es) 2013-05-30
WO2012052384A1 (en) 2012-04-26
US8986987B2 (en) 2015-03-24
CN103370079A (zh) 2013-10-23
EP2629794B1 (en) 2017-06-07
EP2629794A1 (en) 2013-08-28
PL2629794T3 (pl) 2017-10-31
MX344069B (es) 2016-12-02
CN103370079B (zh) 2016-08-10
US20130230556A1 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
ES2635019T3 (es) Vacuna con vector del herpesvirus de pavo contra la gripe aviar en aves de corral
Bano et al. Evaluation of pathogenic potential of avian influenza virus serotype H9N2 in chickens
Middleton et al. Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks
Bublot et al. Development and use of fowlpox vectored vaccines for avian influenza
Bublot et al. Efficacy of a fowlpox-vectored avian influenza H5 vaccine against Asian H5N1 highly pathogenic avian influenza virus challenge
Bensink et al. Newcastle disease virus strain I2–a prospective thermostable vaccine for use in developing countries
Shortridge et al. Interspecies transmission of influenza viruses: H5N1 virus and a Hong Kong SAR perspective
Beato et al. A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1
Kilany et al. Comparison of the effectiveness of rHVT-H5, inactivated H5 and rHVT-H5 with inactivated H5 prime/boost vaccination regimes in commercial broiler chickens carrying MDAs against HPAI H5N1 clade 2.2. 1 virus
RU2010116187A (ru) Способ получения вируса гриппа
Kapczynski et al. Influenza vaccines for avian species
Beato et al. Transboundary spread of highly pathogenic avian influenza through poultry commodities and wild birds: a review
Yoo et al. Anti-infective potential of catechins and their derivatives against viral hepatitis
AR099470A1 (es) Vacunas de virus de aves de corral líquidas
Zeng et al. Protective efficacy of an H5N1 inactivated vaccine against challenge with lethal H5N1, H5N2, H5N6, and H5N8 influenza viruses in chickens
Yiu Lai et al. Human H7N9 avian influenza virus infection: a review and pandemic risk assessment
Amirsalehy et al. Can dogs carry the global pandemic candidate avian influenza virus H9N2?
Skarlupka et al. Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses
Ingrao et al. Characterization of two recombinant HVT-IBD vaccines by VP2 insert detection and cell-mediated immunity after vaccination of specific pathogen-free chickens
Iqbal Progress toward the development of polyvalent vaccination strategies against multiple viral infections in chickens using herpesvirus of turkeys as vector
Balzli et al. The efficacy of recombinant turkey herpesvirus vaccines targeting the H5 of highly pathogenic avian influenza virus from the 2014–2015 North American outbreak
Oliveira Cavalcanti et al. A genetically engineered H5 protein expressed in insect cells confers protection against different clades of H5N1 highly pathogenic avian influenza viruses in chickens
Sarwar et al. Prevalence of Avian Influenza Viruses in live bird markets of Lahore.
Bublot et al. Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand
Terregino et al. Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2. 1 by means of serological and in vivo tests